Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.31 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.31 |
| ▸ | RARA | P10276 | 1/20 | 0.30 |
| ▸ | RARG | P13631 | 1/20 | 0.30 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6368904 | 0.72 | RARB (0.43) | RARBCYP1A2HAO1ALDH1A1LMNA | |
| SCHEMBL9580605 | 0.71 | RARB (0.38) | RARBCYP1A2HAO1ALDH1A1LMNA | |
| SCHEMBL6685549 | 0.71 | RARB (0.38) | RARBCYP1A2HAO1ALDH1A1LMNA | |
| SCHEMBL11412206 | 0.70 | RARB (0.42) | RARBCYP1A2ALDH1A1LMNAPTGS1 | |
| SCHEMBL3346411 | 0.69 | RARB (0.41) | RARBCYP1A2ALDH1A1LMNAPTGS1 | |
| SCHEMBL10748262 | 0.68 | ALDH1A1 (0.43) | RARBCYP1A2HAO1ALDH1A1LMNA | |
| SCHEMBL10748261 | 0.68 | ALDH1A1 (0.43) | RARBCYP1A2HAO1ALDH1A1LMNA | |
| SCHEMBL11372973 | 0.68 | — | — | |
| SCHEMBL13950640 | 0.67 | KRAS (0.39) | RARBCYP1A2HAO1ALDH1A1LMNA | |
| SCHEMBL5267535 | 0.67 | RARB (0.38) | RARBCYP1A2HAO1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1442014-B1 | MANUFACTURE OF RETINOIDS | DSM IP ASSETS BV (NL) | 2007-03-21 | — | — | EP | claimed |
| US-7067703-B2 | Manufacture of retinoids | DSM IP ASSETS B.V. (NL) | 2006-06-27 | — | — | US | claimed |
| US-20050014976-A1 | Manufacture of retinoids | DSM IP ASSETS B.V. (NL) | 2005-01-20 | — | — | US | claimed |
| EP-1442014-A1 | MANUFACTURE OF RETINOIDS | DSM IP Assets B.V. (NL) | 2004-08-04 | — | — | EP | claimed |
| WO-2003037856-A1 | MANUFACTURE OF RETINOIDS | DSM IP ASSETS B.V. (NL) | 2003-05-08 | — | — | WO | claimed |
| EP-1442014-B1 | MANUFACTURE OF RETINOIDS | DSM IP ASSETS BV (NL) | 2007-03-21 | — | — | EP | disclosed |
| EP-1442014-B1 | MANUFACTURE OF RETINOIDS | DSM IP ASSETS BV (NL) | 2007-03-21 | — | — | EP | disclosed |
| CN-1261411-C | Preparation of retinoids | DSM IP ASSETS BV (NL) | 2006-06-28 | — | — | CN | disclosed |
| US-7067703-B2 | Manufacture of retinoids | DSM IP ASSETS B.V. (NL) | 2006-06-27 | — | — | US | disclosed |
| US-7067703-B2 | Manufacture of retinoids | DSM IP ASSETS B.V. (NL) | 2006-06-27 | — | — | US | disclosed |
| CN-1582273-A | Preparation of retinoids | DSM IP ASSETS BV (NL) | 2005-02-16 | — | — | CN | disclosed |
| US-20050014976-A1 | Manufacture of retinoids | DSM IP ASSETS B.V. (NL) | 2005-01-20 | — | — | US | disclosed |
| US-20050014976-A1 | Manufacture of retinoids | DSM IP ASSETS B.V. (NL) | 2005-01-20 | — | — | US | disclosed |
| EP-1442014-A1 | MANUFACTURE OF RETINOIDS | DSM IP Assets B.V. (NL) | 2004-08-04 | — | — | EP | disclosed |
| EP-1442014-A1 | MANUFACTURE OF RETINOIDS | DSM IP Assets B.V. (NL) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003037856-A1 | MANUFACTURE OF RETINOIDS | DSM IP ASSETS B.V. (NL) | 2003-05-08 | — | — | WO | disclosed |
| WO-2003037856-A1 | MANUFACTURE OF RETINOIDS | DSM IP ASSETS B.V. (NL) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014976-A1 | Manufacture of retinoids | RXRA, ALDH1A2, RXRB | RARB 5/4885CYP1A2 516/4885HAO1 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.